Eurofins to Divest Its Electrical & Electronic Testing Business

Regulatory News:

Eurofins Scientific SE (the “Company” or “Eurofins”) (EUFI.PA) (Paris:ERF) announces the signing of an agreement to divest its Electrical & Electronic Testing business (“MET Labs”) to UL Solutions Inc. for an Enterprise Value of €575 million on a cash and debt free basis. MET Labs is expected to generate over €180 million in revenues in 2026, with profitability broadly in line with the Group average, and employs approximately 1,300 staff globally.

MET Labs is an international network of laboratories offering expertise in product safety testing, inspection and certification services for electrical and electronics products. The business serves clients across consumer electronics, automotive, telecommunications and industrial sectors, ensuring compliance with international safety and performance standards.

As previously communicated, Eurofins is focused on allocating capital toward its core testing for life capabilities. Proceeds from this divestment will support the Group's capital allocation priorities, including debt reduction, capital expenditure in laboratories and owned sites, next-generation digital solutions, robotics and AI developments, share buybacks and strategic acquisitions to further strengthen Eurofins' market-leading positions in food, environmental, pharmaceutical, clinical and related testing areas.

Completion of the transaction is subject to customary regulatory approvals and is expected to occur by the end of 2026.

Notes to Editors:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.